Phase ii study on lapatinib in advanced egfr-positive chordoma

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1931-1936

  Stacchiotti, S ^a   Tamborini, E ^a   Lo Vullo, S ^a   Bozzi, F ^a   Messina, A ^a   Morosi, C ^a   Casale, A ^a   Crippa, F ^a   Conca, E ^a   Negri, T ^a   Palassini, E ^a   Marrari, A ^a   Palmerini, E ^b   Mariani, L ^a   Gronchi, A ^a   Pilotti, S ^a   Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Chemotherapy; Chordoma; EGFR; Lapatinib; Sarcoma; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHORDOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR LOCALIZATION;

CHEMOTHERAPY; CHORDOMA; EGFR; LAPATINIB; SARCOMA; TYROSINE KINASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHORDOMA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SACRUM; SKULL BASE; TREATMENT OUTCOME;

EID: 84883773689     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt117     Document Type: Article

References (25)

1. Newton H. Chordoma. In Raghavan D, Brecher ML, Johnson DH et al. (eds), Textbooks of Uncommon Cancer. 3rd edition. Chichester, UK: John Wiley & Sons Ltd. 2006; 614-625.
2. Delaney TF, Liebsch NJ, Pedlow FX et al. Phase II study of high-dose photon/ proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 732-739.
3. Yasuda M, Bresson D, Chibbaro S et al. Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients. Neurosurg Rev 2012; 35: 171-182.
4. Samii A, Gerganov VM, Herold C et al. Chordomas of the skull base: surgical management and outcome. J Neurosurg 2007; 107: 319-324.
5. Stacchiotti S, Casali PG, Lo Vullo S et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010; 17: 211-219.
6. McMaster ML, Goldstein AM, Bromley CM et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12: 1-11.
7. McPherson CM, Suki D, McCutcheon IE et al. Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine 2006; 5: 277-280.
8. Scimeca PG, James-Herry AG, Black KS et al. Chemotherapeutic treatment of malignant chordomas in children. J Pediatr Hematol Oncol 1996; 18: 237-240.
9. Razis DV, Tsatsaronis A, Kyriazides I et al. Chordoma of the cervical spine treated with vincristine sulphate. J Med 1974; 5: 274-277.
10. McSweeney AJ, Sholl PR. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordomas therapy. AMA Arch Surg 1959; 79: 152-155.
11. Chugh R, Dunn R, Zalupski MM et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005; 23: 3597-3604.
12. Stacchiotti S, Longhi A, Ferraresi V et al. A phase II study on imatinib in advanced chordoma. J Clin Oncol 2012; 30: 914-920.
13. Stacchiotti S, Marrari A, Tamborini E et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009; 20: 1886-1894.
14. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of non gastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-3160.
15. Weinberger PM, Yu Z, Kowalski D et al. Differential expression of EGFR, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005; 131: 707-711.
16. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29: 572-574.
17. Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 2009; 20: 953-955.
18. Lindén O, Stenberg L, Kjellén E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol 2009; 48: 158-159.
19. Tamborini E, Virdis E, Negri T et al. Analysis of receptor tyrosine kinases and downstream pathways in chordoma. Neuro Oncol 2010; 12: 776-789.
20. Shalaby A, Presneau N, Ye H et al. The role of EGFR in chordoma pathogenesis: a potential therapeutic target. J Pathol 2011; 223: 336-346.
21. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
22. Choi H, Charnsangavej C, Faria SC et al. Correlation of CT and PET in patients with metastatic GIST treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
23. Stacchiotti S, Collini P, Messina A et al. Tumor response assessment in high grade soft tissue sarcomas: a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. Radiology 2009; 251: 447-456.
24. Eisenhauer EA, Therasse P, Bogaert J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
25. Kaplan WE, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.